Skip to main content
BioInvent International logo

BioInvent International — Investor Relations & Filings

Ticker · BINV ISIN · SE0015244520 LEI · 549300E7QRHEF2IJUY10 ST Manufacturing
Open in API
Filings indexed 679 across all filing types
Latest filing 2026-05-21 Regulatory Filings
Country SE Sweden
Listing ST BINV

About BioInvent International

https://www.bioinvent.com/en

BioInvent International is a clinical-stage company that discovers and develops novel, first-in-class immuno-modulatory antibodies for cancer therapy. Leveraging extensive expertise in immunology, cancer biology, and antibody biology, the company generates innovative immuno-oncology drug candidates for its clinical pipeline. BioInvent's operations include an in-house manufacturing facility to produce antibodies for its preclinical studies and clinical trials, with the goal of developing treatments that can transform the lives of cancer patients.

Recent filings

Filing Released Lang Actions
BioInvent presenterar solida data på ASCO för behandling av långt framskriden äggstockscancer med TNFR2-antikroppen BI-1808 och KEYTRUDA® (pembrolizumab)
Regulatory Filings Classification · 70% confidence The document is clearly a corporate press release (“Pressmeddelande”) announcing clinical trial data presented at the ASCO conference. It does not contain financial statements, management/Q&A transcripts, dividend notices, governance or ESG reports, M&A details, or any regulatory form like a 10-K or interim report. It is a general corporate announcement required under EU market abuse rules but is not a detailed investor presentation or formal report itself. Thus it falls into the fallback “Regulatory Filings” category.
2026-05-21 Swedish
BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA® (pembrolizumab) in Advanced Ovarian Cancer at ASCO
Regulatory Filings Classification · 90% confidence The document is a corporate press release announcing clinical trial data and ASCO poster presentation details, not a financial report or earnings announcement. It discloses information under the EU Market Abuse Regulation as a regulatory announcement rather than containing substantive financials or investor slides. It does not fit other specific filing types, so it falls under the general Regulatory Filings category.
2026-05-21 English
Resolutions at BioInvent’s Annual General Meeting 2026
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a press release summarizing the resolutions adopted at BioInvent’s Annual General Meeting 2026, including election of board members, approval of financial statements, fee resolutions, incentive programs, share issues, and authorizations. It reports the outcomes of shareholder votes and formal AGM resolutions. This aligns with "Declaration of Voting Results & Voting Rights Announcements" (DVA).
2026-04-29 English
Beslut på BioInvents årsstämma 2026
AGM Information Classification · 94% confidence The document is a press release summarizing the resolutions and decisions taken at BioInvent’s 2026 Annual General Meeting, including board elections, approval of financial statements, discharge of liability, auditor appointment, incentive program approvals, and share issuance authorizations. This matches the definition of AGM Information (materials and outcomes from an AGM).
2026-04-29 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 90% confidence The document is titled “Delårsrapport 1 januari – 31 mars 2026” (Interim Report for January 1 – March 31, 2026). It contains detailed financial tables for the first quarter, management commentary (VD comments), operational and clinical program updates, and outlook – all hallmarks of a comprehensive quarterly interim report rather than an announcement or presentation. Therefore, it fits the Interim / Quarterly Report category. Q1 2026
2026-04-29 Swedish
Interim / Quarterly Report 2026
Interim / Quarterly Report Classification · 92% confidence The document is titled “Interim Report January 1 – March 31, 2026” for BioInvent International AB (publ), covering first quarter financial performance. It includes actual financial statements (net sales, profit/loss, cash flows), detailed management commentary (CEO comments), business highlights, and clinical program updates. This matches the definition of an Interim/Quarterly Report (IR), not merely an announcement or presentation. Hence, it should be classified as IR. Q1 2026
2026-04-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.